The aim of the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Adjuvant Breast Cancer (ABC) Trial is to evaluate whether adding chemotherapy and/or ovarian suppression to tamoxifen is effective and cost-effective in the treatment of women with early breast cancer.

All women recruited to the trial receive tamoxifen. For pre/peri-menopausal women, there are three randomisation options:

• chemotherapy versus no chemotherapy;
• ovarian suppression versus no ovarian suppression;
• chemotherapy versus no chemotherapy and ovarian suppression versus no ovarian suppression.

Post-menopausal women are randomised to chemotherapy or no chemotherapy.

The trial's primary outcome measures are overall and relapse free survival and will be examined for two principal comparisons: ± ovarian suppression in pre/peri-menopausal women, and ± chemotherapy for all women. The economic evaluation also carried out for these comparisons uses patient-specific and published resource use data relating to adjuvant therapies, treatments for any therapy induced toxicities and recurrences, and numbers of visits made to GPs, outpatient clinics and other health care professionals. Patient outcome is measured as both survival and quality adjusted survival (or QALYs), calculated by weighting survival by health state utilities derived by administering the EuroQol EQ-5D questionnaire to a sub-group of patients in the trial.

The economic evaluation conducted alongside this trial has now been completed. The manuscript reporting the findings is soon to be submitted for publication.

	Economic Evaluation of Healthcare Technologies/Clinical Trials - Completed Studies
	Measurement and Valuation of Resources/Estimating costs for economic evaluation